Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.10
-0.08 (-0.98%)
At close: Jun 11, 2026, 4:00 PM EDT
8.04
-0.06 (-0.74%)
After-hours: Jun 11, 2026, 5:22 PM EDT

Immix Biopharma Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Immix Biopharma stock has a consensus rating of "Buy" and an average price target of $18.46. The average 1-year stock price forecast is 127.90% higher than the current stock price, while the lowest is $14.5 (+79.01%) and the highest is $22.78 (+181.23%).

Price Target: $18.46 (+127.90%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$14.5$18.46$20$22.78
Change+79.01%+127.90%+146.91%+181.23%

Analyst Ratings

The average analyst rating for Immix Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy112222
Buy000222
Hold000000
Sell000000
Strong Sell000000
Total112444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Mizuho Securities
Mizuho Securities
Buy
Maintains
$15
BuyMaintains$15+85.19%May 26, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$15$20
BuyReiterates$15$20+146.91%May 22, 2026
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$20
BuyReiterates$20+146.91%Mar 25, 2026
Citizens JMP
Citizens JMP
Buy
Initiates
$23
BuyInitiates$23+183.95%Mar 9, 2026

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
56.42M
EPS This Year
-0.70
from -0.89
EPS Next Year
-0.65
from -0.70
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-1.35M-8.22M-16.14M-22.67M-29.96M-45.43M
Net Income
-24.38M-8.23M-15.43M-21.61M-29.44M-41.25M
EPS
-----0.89-0.70
Free Cash Flow
-2.10M-4.31M-5.94M-7.55M-13.61M-35.80M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-
Avg-0.70
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-